id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-N-0472-0003,FDA,FDA-2009-N-0472,"Reference 2 -  Order Classifying  XDx AlloMap Test, dated August 26, 2008  [ Background material FDA-2009-N-0472-0001]",Supporting & Related Material,BKG-Background Material,2009-10-21T04:00:00Z,2009,10,,,2009-10-22T19:29:32Z,,0,0,0900006480a47982
FDA-2009-N-0472-0002,FDA,FDA-2009-N-0472,"Reference 1 - Petition from XDx, Inc. dated August 15, 2008  [ Background material FDA-2009-N-0472-0001]",Supporting & Related Material,BKG-Background Material,2009-10-21T04:00:00Z,2009,10,,,2009-10-22T19:28:57Z,,0,0,0900006480a478f3
FDA-2009-N-0472-0001,FDA,FDA-2009-N-0472,Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Cardiac Allograft,Rule,NFR-Notice of Final Rule,2009-10-21T04:00:00Z,2009,10,2009-10-21T04:00:00Z,,2009-10-21T20:51:55Z,E9-25315,0,0,0900006480a47214